

Quaker Chemical Corporation Announces Second Quarter 2012 Results

July 30, 2012

- -- Net sales up 5% from the second guarter of 2011
- -- Net income up 7% from the second quarter of 2011
 - -- Quarterly operating cash flow of \$15.2 million

CONSHOHOCKEN, Pa., July 30, 2012 /PRNewswire/ — Quaker Chemical Corporation (NYSE: KWR) today announced net sales of \$167.8 million for the second quarter of 2012, up 5% compared to second quarter 2011 net sales of \$167.8 million. Net income of \$10.5 million and earnings per diluted share of \$0.81 for the second quarter of 2012 were up 7% and 3%, respectively, compared to \$9.8 million and \$0.79 earnings per diluted share for the second quarter of 2011. For the first six months of 2012, the Company reported net sales of \$354.4 million, up 8% compared to net sales of \$327.7 million for the first six months of 2011. Net income of \$2.2.5 million and earnings per diluted share of \$1.72 for the first six months of 2012 were up 10% and 2%, respectively, compared to net income of \$20.4 million and earnings per diluted share of \$1.69 for the first six months of 2011 includes charges of approximately \$0.06 per diluted share for certain customer bankruptcies in the U.S. and \$0.03 per diluted share related to CFO transition costs. The second quarter and first half of 2012 earnings per diluted share include an approximate \$0.03 and \$0.11 dilutive effect as a result of the Company's equity offering in May 2011, respectively.

Michael F. Barry, Chairman, Chief Executive Officer and President, commented, "We are pleased with the second quarter results, especially in light of the bankruptcy and CFO transition charges. We are being negatively impacted by a stronger dollar and weaker demand in several geographical areas such as Europe, China, Brazil and India. However, these negatives have been offset by additional new business and our recent acquisitions as well as the continuing manufacturing recovery of North America. Looking forward to the second half, we expect the global economic environment to remain challenging, with continued weakness in most regions. However, I remain confident that 2012 will be another good year for Quaker. In addition, our strong balance sheet and cash flow generation continues to provide us the financial flexibility to invest in our strategic growth initiatives, pay dividends to our shareholders, and grow our Company further via acquisition."

Second Quarter 2012 Summary

Net sales for the second quarter of 2012 were \$176.8 million, an increase of 5% from \$167.8 million in the second quarter of 2011. Product volumes, including acquisitions, were higher by 6%, selling price and mix increased revenues by 5%, while foreign exchange rates decreased revenues by 6%.

Gross profit increased by \$6.9 million, or 13%, from the second quarter of 2011. The second quarter of 2012 gross margin increased to 34.3% from 32.0% for the second quarter of 2011 and 33.7% for the first quarter of 2012. The increase in gross margin reflects the Company's ongoing initiative of restoring margins to more acceptable levels through price increases, as well as mix effects experienced in the quarter.

Selling, general and administrative expenses ("SG&A") increased approximately \$4.8 million compared to the second quarter of 2011, primarily related to acquisitions and higher selling, inflationary and other costs on increased business activity, which were partially offset by decreases due to foreign exchange rate translation. The second quarter of 2012 SG&A includes charges of approximately \$0.06 per diluted share for certain customer bankruptcies in the U.S. and \$0.03 per diluted share related to CFO transition costs. As a result, the second quarter of 2012 SG&A, as a percentage of sales, increased to 24.7% compared to 23.1% for the second quarter of 2011 and 24.3% for the first quarter of 2012.

Other income decreased in the second quarter of 2012 primarily due to foreign exchange losses compared to foreign exchange gains in the second quarter of 2011. Interest expense in the second quarter of 2012 was comparable to the second quarter of 2011, however, decreases in interest expense due to lower average borrowings were partially offset by increases related to the accretion of certain acquisition-related liabilities.

The second quarter of 2012 earnings per diluted share of \$0.81 reflects an approximate \$0.03 dilutive effect as a result of the Company's equity offering in May of 2011.

Year-to-Date Summary

Net sales for the first half of 2012 were \$354.4 million, an increase of 8% from \$327.7 million in the first half of 2011. Product volumes, including acquisitions, were higher by 5%, selling price and mix increased revenues by 7%, while foreign exchange rates decreased revenues by 4%.

Gross profit increased by \$13.9 million, or 13%, from the first half of 2011 with gross margin increasing to 34.0% from 32.5% for the first half of 2011, reflecting the Company's ongoing initiative of restoring margins and mix effects noted above.

SG&A increased approximately \$9.3 million compared to the first half of 2011, primarily related to acquisitions and higher selling, inflationary and other costs on increased business activity, which were partially offset by decreases due to foreign exchange rate translation. The first half of 2012 SG&A includes the bankruptcy charges and CFO transition costs, as discussed above. SG&A, as a percentage of sales, increased to 24.5% from 23.6% for the first half of 2011.

Other income decreased in the first half of 2012 primarily due to higher foreign exchange losses and lower third party license fees as compared to the first half of 2011. Interest expense was relatively flat compared to the first half of 2011, however, decreases in interest expense due to lower average borrowings were offset by increases related to the accretion of certain acquisition-related liabilities.

The Company's low year-to-date 2012 and 2011 effective tax rates of 26.1% and 25.7%, respectively, reflect decreases in reserves for uncertain tax positions due to the expiration of applicable statutes of limitations for certain tax years of approximately \$0.12 and \$0.11 per diluted share, respectively. The Company has experienced and expects to further experience volatility in its effective tax rates due to the varying timing of tax audits and the expiration of applicable statutes of limitations as they relate to uncertain tax positions, among other factors.

Equity in net income of associated companies decreased in the first half of 2012 as compared to the first half of 2011, primarily due to the Company's July 2011 purchase of the remaining ownership interest in its Mayican affiliate

The first half of 2012 earnings per diluted share of \$1.72 reflect an approximate \$0.11 dilutive effect as a result of the Company's equity offering in May of 2011.

Balance Sheet and Cash Flow Items

Net operating cash flow of \$15.2 million was generated in the second quarter of 2012, primarily led by the Company's second quarter net income. The Company's consolidated leverage ratio remained strong at less than one times EBITDA.

Subsequent Events

In July 2012, the Company acquired NP Coil Dexter Industries, S.r.I., a European manufacturer and supplier of metal surface treatment products. The acquired business has annual net sales of approximately \$11.0 million.

Forward-Looking Statements

This release contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected in such statements. A major risk is that the Company's demand is largely derived from the demand for its customers' products, which subjects the Company to downturns in a customer's business and unanticipated customer production shutdowns. Other major risks and uncertainties include, but are not limited to, significant increases in raw material costs, customer financial stability, worldwide economic and political conditions, foreign currency fluctuations, and future terrorist attacks such as those that occurred on September 11, 2001. Other factors could also adversely affect us. Therefore, we caution you not to place undue reliance on our forward-looking statements. This discussion is provided as permitted by the Private Securities Litigation Reform Act of 1995.

Conference Cal

As previously announced, Quaker Chemical's investor conference call to discuss second quarter results is scheduled for July 31, 2012 at 8:30 a.m. (ET). A live webcast of the conference call, together with supplemental information, can be accessed through the Company's Investor Relations Web site at http://www.guakerchem.com. You can also access the conference call by dialing 877-269-7756.

About Quake

Quaker Chemical Corporation is a leading global provider of process chemicals, chemical specialties, services, and technical expertise to a wide range of industries – including steel, aluminum, automotive, mining, aerospace, tube and pipe, coatings, and construction materials. Our products, technical solutions, and chemical management services enhance our customers' processes, improve their product quality, and lower their costs. Quaker's headquarters is located near Philadelphia in Conshohocken, Pennsylvania.

(Dollars in thousands, except per share data)

	(Unaudited)								
	Three Months End		Ended Jun	nded June 30,		Six Months Er		nded June 30,	
		2012 2011		2012		2011			
Net sales	\$	176,797	\$	167,792	\$	354,435	\$	327,657	
Cost of goods sold	-	116,161		114,026		234,004		221,157	
Gross profit %		60,636 34.3%		53,766 32.0%		120,431 34.0%		106,500 32.5%	
Selling, general and administrative expenses		43,653		38,825		86,746		77,459	
Operating income %		16,983 9.6%		14,941 8.9%		33,685 9.5%		29,041 8.9%	
Other (expense) income, net Interest expense Interest income Income before taxes and equity in net income of associated companies		(134) (1,151) 137 15,835		791 (1,200) 271 14,803		207 (2,325) 260 31,827		1,330 (2,418) 543 28,496	
Taxes on income before equity in net income of associated companies Income before equity in net income of associated companies		4,874 10,961		4,499 10,304		8,319 23,508		7,321 21,175	
Equity in net income of associated companies	-	209		251		355		610	
Net income		11,170		10,555		23,863		21,785	
Less: Net income attributable to noncontrolling interest		630		714		1,377		1,344	
Net income attributable to Quaker Chemical Corporation %	\$	10,540 6.0%	\$	9,841 5.9%	\$	22,486 6.3%	\$	20,441 6.2%	
Per share data: Net income attributable to Quaker Chemical Corporation Common Shareholders - basic Net income attributable to Quaker Chemical Corporation Common Shareholders- diluted	\$ \$	0.81 0.81	\$ \$	0.80 0.79	\$ \$	1.74 1.72	\$ \$	1.72 1.69	

Quaker Chemical Corporation Condensed Consolidated Balance Sheet (Dollars in thousands, except par value and share amounts)

	(Unaudited)				
	June 30, 2012		December 31, 2011		
ASSETS					
Current assets					
Cash and cash equivalents	\$	25,252	\$	16,909	
Accounts receivable, net		156,424		150,676	
Inventories, net		77,678		74,758	
Prepaid expenses and other current assets		18,009		17,206	
Total current assets		277,363		259,549	
Property, plant and equipment, net		82,655		82,916	
Goodwill		57,033		58,152	
Other intangible assets, net		30,397		31,783	
Investments in associated companies		7,891		7,942	
Deferred income taxes		27,644		29,823	
Other assets		36,370		35,356	
Total assets	\$	519,353	\$	505,521	
LIABILITIES AND EQUITY Current liabilities					
Short-term borrowings and current portion of long-term debt	\$	563	\$	636	
Accounts and other payables	•	74,679	•	68,125	
Accrued compensation		10,610		16,987	
Other current liabilities		22,334		20,901	
Total current liabilities		108,186		106,649	
Long-term debt		45,004		46,701	
Deferred income taxes		6,622		7,094	
Other non-current liabilities		86,116		89,351	
Total liabilities		245,928		249,795	
Equity					
Common stock, \$1 par value; authorized 30,000,000 shares; issued 13,010,639 shares		13,011		12,912	
Capital in excess of par value		92,199		89,725	
Retained earnings		192,116		175,932	
Accumulated other comprehensive loss		(32,091)		(29,820)	
Total Quaker shareholders' equity		265,235		248,749	
Noncontrolling interest		8,190		6,977	
Total equity		273,425		255,726	
Total liabilities and equity	\$	519,353	\$	505,521	
- 11- V					

Quaker Chemical Corporation Condensed Consolidated Statement of Cash Flows For the six months ended June 30, (Dollars in thousands)

Cash flows from operating activities 2012 2011 Net income \$ 23,863 \$ 21,785 Adjustments to reconcile net income to net cash provided by operating activities: \$ 5,969 \$ 5,405 Depreciation \$ 1,465 973 Equity in undistributed earnings of associated companies, net of dividends \$ 1,716 32 Equity in undistributed earnings of associated companies, net of dividends \$ 1,332 \$ 4,162 Equity in undistributed earnings of associated companies, net of dividends \$ 1,332 \$ 4,162 Equity in undistributed earnings of associated companies, net of dividends \$ 1,332 \$ 4,162 Equity in undistributed earnings of associated companies, net of dividends \$ 1,332 \$ 4,162 Editor-Chasade of prospation and other, net \$ 1,864 \$ 1,864 Gain on disposal of property, plant and equipment \$ (1,80) \$ (80) \$ (80) Investing and on disposal of property, plant and equipment \$ (1,80) \$ (80) \$ (804) Pension and other postretiement benefits \$ (3,871) \$ (17,396) \$ (80) (Decrease) increase in cash from changes in current assets and current liabilities, net of acquisitions acquisitions acquisition		(Unaudited)			
Net income \$ 23,863 \$ 21,785 Adjustments to reconcile net income to net cash provided by operating activities: 5,969 5,405 Depreciation 1,465 973 Equity in undistributed earnings of associated companies, net of dividends (171) (32) Deferred compensation and other, net 1,332 4,162 Stock-based compensation and other, net (13) (78) Gain on disposal of property, plant and equipment (13) (78) Insurance settlement realized (808) (864) Pension and other postretrement benefits (1,951) (4,168) (Decrease) increase in cash from changes in current assets and current liabilities, net of acquisitions: (7,031) (17,392) Accounts receivable (3,871) (13,986) (40,029) Inventories (3,871) (13,986) (40,029) Accounts payable and accrued liabilities 2,1941 167 Net cash provided by operating activities (6,423) (6,641) Payments related to acquisitions (6,423) (6,641) Payments related to acquisition of assets 84 2221<					2011
Adjustments to reconcile net income to net cash provided by operating activities: Depreciation	Cash flows from operating activities				
Depreciation	Net income	\$	23,863	\$	21,785
Amortization 1,465 973 Equity in undistributed earnings of associated companies, net of dividends (171) (32) Deferred compensation and other, net 1,332 4,162 Stock-based compensation 2,078 1,854 Gain on disposal of property, plant and equipment (13) (78) Insurance settlement realized (808) (864) Pension and other postretirement benefits (808) (864) (Decrease) in crease in cash from changes in current assets and current liabilities, net of acquisitions: (7,031) (17,392) Accounts receivable (7,031) (17,392) Inventories (3,871) (13,986) Prepaid expenses and other current assets (1,946) (4,029) Accounts payable and accrued liabilities 3,025 6,537 Net cash provided by operating activities 21,941 167 Cash flows from investing activities (6,641) (6,641) Payments related to acquisitions - (7171) Proceeds from disposition of assets 8 221 Insurance settlement received and interest earned	Adjustments to reconcile net income to net cash provided by operating activities:				
Equity in undistributed earnings of associated companies, net of dividends (171) (32) Deferred compensation and other, net 1,332 4,162 Stock-based compensation 2,078 1,854 Gain on disposal of property, plant and equipment (13) (78) Insurance settlement realized (808) (864) Pension and other postretirement benefits (1,951) (4,168) (Decrease) increase in cash from changes in current assets and current liabilities, net of acquisitions: (7,031) (17,392) Accounts receivable (7,031) (13,986) Prepaid expenses and other current assets (3,871) (13,986) Prepaid expenses and other current assets (1,946) (4,029) Accounts payable and accrued liabilities 3,025 6,537 Net cash provided by operating activities 21,941 167 Cash flows from investing activities (6,423) (6,641) Payments related to acquisitions - (717) Proceeds from disposition of assets 84 221 Insurance settlement received and interest earned 35 42 Change in res	Depreciation		5,969		5,405
Deferred compensation and other, net 1,332 4,162 Stock-based compensation 2,078 1,854 Gain on disposal of property, plant and equipment (13) (78) Insurance settlement realized (808) (864) Pension and other postretirement benefits (1,951) (4,168) (Decrease) increase in cash from changes in current assets and current liabilities, net of acquisitions: (7,031) (17,392) Accounts receivable (7,031) (17,392) Inventories (3,871) (13,986) Prepaid expenses and other current assets (1,946) (4,029) Accounts payable and accrued liabilities 3,025 6,537 Net cash provided by operating activities 3,025 6,537 Net cash provided by operating activities (6,423) (6,641) Payments related to acquisitions (6,423) (6,641) Payments related to acquisitions (6,423) (6,641) Payments related to acquisitions of assets 84 221 Insurance settlement received and interest earned 35 42 Change in restricted cash, net 773	Amortization		1,465		973
Stock-based compensation 2,078 1,854 Gain on disposal of property, plant and equipment (13) (78) Insurance settlement realized (808) (864) Pension and other postretirement benefits (1,951) (4,168) (Decrease) increase in cash from changes in current assets and current liabilities, net of acquisitions: 7(7,031) (17,392) Accounts receivable (7,031) (13,986) Prepaid expenses and other current assets (1,946) (4,029) Accounts payable and accrued liabilities 3,025 6,537 Net cash provided by operating activities 21,941 167 Cash flows from investing activities (6,423) (6,641) Payments related to acquisitions - (717) Proceeds from disposition of assets 84 221 Insurance settlement received and interest earned 35 42 Change in restricted cash, net 773 822 Net cash used in investing activities (5,531) (6,273) Cash flows from financing activities (1,754) (40,402) Dividends paid (6,213) <td>Equity in undistributed earnings of associated companies, net of dividends</td> <td></td> <td>(171)</td> <td></td> <td>(32)</td>	Equity in undistributed earnings of associated companies, net of dividends		(171)		(32)
Gain on disposal of property, plant and equipment Insurance settlement realized (808) (864) Pension and other postretirement benefits (1,951) (4,168) Pension and other postretirement benefits (1,951) (4,168) (Decrease) increase in cash from changes in current assets and current liabilities, net of acquisitions: (7,031) (17,392) Inventories (3,871) (13,986) (4,029) Inventories (1,946) (4,029) Accounts payable and accrued liabilities 3,025 6,537 Net cash provided by operating activities 21,941 167 Cash flows from investing activities (6,423) (6,641) Payments related to acquisitions - (717) Proceeds from disposition of assets 84 221 Insurance settlement received and interest earned 35 42 Change in restricted cash, net 773 822 Net cash used in investing activities (5,531) (6,273) Cash flows from financing activities (1,754) (40,402) Dividends paid (6,213) (5,413) Stock options	Deferred compensation and other, net		1,332		4,162
Insurance settlement realized (808) (864) Pension and other postretirement benefits (1,951) (4,168) (Decrease) increase in cash from changes in current assets and current liabilities, net of acquisitions: (7,031) (17,392) Accounts receivable (7,031) (13,986) (4,029) Inventories (1,946) (4,029) Accounts payable and accrued liabilities 3,025 6,537 Net cash provided by operating activities 21,941 167 Cash flows from investing activities (6,423) (6,641) Payments related to acquisitions - (717) Proceeds from disposition of assets 84 221 Insurance settlement received and interest earned 35 42 Change in restricted cash, net 773 822 Net cash used in investing activities (5,531) (6,273) Cash flows from financing activities (6,213) (5,531) Cash flows from financing activities (6,213) (5,531) Cash flows from financing activities (6,213) (5,413) Stock options exercised, other	Stock-based compensation		2,078		1,854
Pension and other postretirement benefits (1,95f) (4,168) (Decrease) in cash from changes in current assets and current liabilities, net of acquisitions: 7,031) (17,392) Accounts receivable (3,871) (13,986) Inventories (3,871) (13,986) Prepaid expenses and other current assets (1,946) (4,029) Accounts payable and accrued liabilities 3,025 6,537 Net cash provided by operating activities 21,941 167 Cash flows from investing activities (6,423) (6,641) Payments related to acquisitions - (717) Proceeds from disposition of assets 84 221 Insurance settlement received and interest earned 35 42 Change in restricted cash, net 773 822 Net cash used in investing activities (5,531) (6,273) Cash flows from financing activities (5,531) (6,273) Cash flows from financing activities (1,754) (40,402) Dividends paid (6,213) (5,413) Stock options exercised, other (925) 146	Gain on disposal of property, plant and equipment		(13)		(78)
Commonstrates Commonstrate	Insurance settlement realized		(808)		(864)
Accounts receivable Inventories (7,031) (17,392) Inventories (3,871) (13,986) Prepaid expenses and other current assets (1,946) (4,029) Accounts payable and accrued liabilities 3,025 6,537 Net cash provided by operating activities 21,941 167 Cash flows from investing activities (6,423) (6,641) Payments related to acquisitions - (717) Proceeds from disposition of assets 84 221 Insurance settlement received and interest earned 35 42 Change in restricted cash, net 773 822 Net cash used in investing activities (5,531) (6,273) Cash flows from financing activities (5,531) (6,273) Cash flows from financing activities (6,213) (5,131) Repayments of long-term debt (1,754) (40,402) Dividends paid (6,213) (5,413) Stock options exercised, other (925) 146 Proceeds from sale of common stock, net of related expenses 1,420 162 Distributio	Pension and other postretirement benefits		(1,951)		(4,168)
Inventories (3,871) (13,986 Prepaid expenses and other current assets (1,946) (4,029 Accounts payable and accrued liabilities 3,025 6,537 Net cash provided by operating activities 21,941 167 Cash flows from investing activities (6,423) (6,641 7,717 7,000	(Decrease) increase in cash from changes in current assets and current liabilities, net of acquisitions:				
Prepaid expenses and other current assets (1,946) (4,029) Accounts payable and accrued liabilities 3,025 6,537 Net cash provided by operating activities 21,941 167 Cash flows from investing activities (6,423) (6,641) Payments related to acquisitions 7 (717) (717) Proceeds from disposition of assets 84 221 Insurance settlement received and interest earned 35 42 Change in restricted cash, net 773 822 Net cash used in investing activities (5,531) (6,273) Cash flows from financing activities (1,754) (40,402) Dividends paid (6,213) (5,413) (5,413) Stock options exercised, other (925) 146 Proceeds from sale of common stock, net of related expenses - 48,143 Excess tax benefit related to stock option exercises 1,420 162 Distributions to noncontrolling shareholders (30) - Net cash (used in) provided by financing activities (7,502) 2,636 Effect of exchange rate changes on cash	Accounts receivable		(7,031)		(17,392)
Accounts payable and accrued liabilities 3,025 6,537 Net cash provided by operating activities 21,941 167 Cash flows from investing activities \$\$\$\$ \$\$\$\$\$\$ (6,641) \$\$\$\$\$\$ (6,641) \$\$\$\$\$\$\$\$ (6,641) \$\$\$\$\$\$\$\$ (717) \$\$\$\$\$\$\$\$ (717) \$\$\$\$\$\$ 42 10,000 \$\$\$\$\$ 42 10,000 <td< td=""><td>Inventories</td><td></td><td>(3,871)</td><td></td><td>(13,986)</td></td<>	Inventories		(3,871)		(13,986)
Net cash provided by operating activities 21,941 167 Cash flows from investing activities (6,423) (6,641) Capital expenditures (6,423) (6,641) Payments related to acquisitions - (717) Proceeds from disposition of assets 84 221 Insurance settlement received and interest earned 35 42 Change in restricted cash, net 773 822 Net cash used in investing activities (5,531) (6,273) Cash flows from financing activities (1,754) (40,402) Dividends paid (6,213) (5,413) Stock options exercised, other (925) 146 Proceeds from sale of common stock, net of related expenses - 48,143 Excess tax benefit related to stock option exercises 1,420 162 Distributions to noncontrolling shareholders (30) - Net cash (used in) provided by financing activities (7,502) 2,636 Effect of exchange rate changes on cash (565) 1,245 Net increase (decrease) in cash and cash equivalents 8,343 (2,225	Prepaid expenses and other current assets		(1,946)		(4,029)
Cash flows from investing activities Capital expenditures (6,423) (6,641) Payments related to acquisitions - (717) Proceeds from disposition of assets 84 221 Insurance settlement received and interest earned 35 42 Change in restricted cash, net 773 822 Net cash used in investing activities (5,531) (6,273) Cash flows from financing activities (1,754) (40,402) Repayments of long-term debt (1,754) (40,402) Dividends paid (6,213) (5,413) Stock options exercised, other (925) 146 Proceeds from sale of common stock, net of related expenses - 48,143 Excess tax benefit related to stock option exercises 1,420 162 Distributions to noncontrolling shareholders (30) - Net cash (used in) provided by financing activities (7,502) 2,636 Effect of exchange rate changes on cash (565) 1,245 Net increase (decrease) in cash and cash equivalents 8,343 (2,225) Cash and cash equivalent	Accounts payable and accrued liabilities		3,025		6,537
Capital expenditures (6,423) (6,641) Payments related to acquisitions - (717) Proceeds from disposition of assets 84 221 Insurance settlement received and interest earned 35 42 Change in restricted cash, net 773 822 Net cash used in investing activities (5,531) (6,273) Cash flows from financing activities (1,754) (40,402) Repayments of long-term debt (1,754) (40,402) Dividends paid (6,213) (5,413) Stock options exercised, other (925) 146 Proceeds from sale of common stock, net of related expenses - 48,143 Excess tax benefit related to stock option exercises 1,420 162 Distributions to noncontrolling shareholders (30) - Net cash (used in) provided by financing activities (7,502) 2,636 Effect of exchange rate changes on cash (565) 1,245 Net increase (decrease) in cash and cash equivalents 8,343 (2,225) Cash and cash equivalents at the beginning of the period 16,909	Net cash provided by operating activities		21,941		167
Capital expenditures (6,423) (6,641) Payments related to acquisitions - (717) Proceeds from disposition of assets 84 221 Insurance settlement received and interest earned 35 42 Change in restricted cash, net 773 822 Net cash used in investing activities (5,531) (6,273) Cash flows from financing activities (1,754) (40,402) Repayments of long-term debt (1,754) (40,402) Dividends paid (6,213) (5,413) Stock options exercised, other (925) 146 Proceeds from sale of common stock, net of related expenses - 48,143 Excess tax benefit related to stock option exercises 1,420 162 Distributions to noncontrolling shareholders (30) - Net cash (used in) provided by financing activities (7,502) 2,636 Effect of exchange rate changes on cash (565) 1,245 Net increase (decrease) in cash and cash equivalents 8,343 (2,225) Cash and cash equivalents at the beginning of the period 16,909	Cash flows from investing activities				
Payments related to acquisitions - (717) Proceeds from disposition of assets 84 221 Insurance settlement received and interest earned 35 42 Change in restricted cash, net 773 822 Net cash used in investing activities (5,531) (6,273) Cash flows from financing activities 8 (2,531) (40,402) Dividends paid (6,213) (5,413) (5,413) Stock options exercised, other (925) 146 Proceeds from sale of common stock, net of related expenses - 48,143 Excess tax benefit related to stock option exercises 1,420 162 162 Distributions to noncontrolling shareholders (30) - - 48,143 Excess tax denefit related by financing activities (7,502) 2,636 Effect of exchange rate changes on cash (565) 1,245 Net increase (decrease) in cash and cash equivalents 8,343 (2,225) Cash and cash equivalents at the beginning of the period 16,909 25,766			(6.423)		(6.641)
Proceeds from disposition of assets 84 221 Insurance settlement received and interest earned 35 42 Change in restricted cash, net 773 822 Net cash used in investing activities (5,531) (6,273) Cash flows from financing activities 8 4 Repayments of long-term debt (1,754) (40,402) Dividends paid (6,213) (5,413) Stock options exercised, other (925) 146 Proceeds from sale of common stock, net of related expenses - 48,143 Excess tax benefit related to stock option exercises 1,420 162 Distributions to noncontrolling shareholders (30) - Net cash (used in) provided by financing activities (7,502) 2,636 Effect of exchange rate changes on cash (565) 1,245 Net increase (decrease) in cash and cash equivalents 8,343 (2,225) Cash and cash equivalents at the beginning of the period 16,909 25,766			-		
Insurance settlement received and interest earned 35 42 Change in restricted cash, net 773 822 Net cash used in investing activities (5,531) (6,273) Cash flows from financing activities 8 4 Repayments of long-term debt (1,754) (40,402) Dividends paid (6,213) (5,413) Stock options exercised, other (925) 146 Proceeds from sale of common stock, net of related expenses - 48,143 Excess tax benefit related to stock option exercises 1,420 162 Distributions to noncontrolling shareholders (30) - Net cash (used in) provided by financing activities (7,502) 2,636 Effect of exchange rate changes on cash (565) 1,245 Net increase (decrease) in cash and cash equivalents 8,343 (2,225) Cash and cash equivalents at the beginning of the period 16,909 25,766			84		
Net cash used in investing activities (5,531) (6,273) Cash flows from financing activities (1,754) (40,402) Repayments of long-term debt (6,213) (5,413) Dividends paid (6,213) (5,413) Stock options exercised, other (925) 146 Proceeds from sale of common stock, net of related expenses - 48,143 Excess tax benefit related to stock option exercises 1,420 162 Distributions to noncontrolling shareholders (30) - Net cash (used in) provided by financing activities (7,502) 2,636 Effect of exchange rate changes on cash (565) 1,245 Net increase (decrease) in cash and cash equivalents 8,343 (2,225) Cash and cash equivalents at the beginning of the period 16,909 25,766			35		42
Net cash used in investing activities (5,531) (6,273) Cash flows from financing activities (1,754) (40,402) Repayments of long-term debt (6,213) (5,413) Dividends paid (6,213) (5,413) Stock options exercised, other (925) 146 Proceeds from sale of common stock, net of related expenses - 48,143 Excess tax benefit related to stock option exercises 1,420 162 Distributions to noncontrolling shareholders (30) - Net cash (used in) provided by financing activities (7,502) 2,636 Effect of exchange rate changes on cash (565) 1,245 Net increase (decrease) in cash and cash equivalents 8,343 (2,225) Cash and cash equivalents at the beginning of the period 16,909 25,766	Change in restricted cash, net		773		822
Repayments of long-term debt (1,754) (40,402) Dividends paid (6,213) (5,413) Stock options exercised, other (925) 146 Proceeds from sale of common stock, net of related expenses - 48,143 Excess tax benefit related to stock option exercises 1,420 162 Distributions to noncontrolling shareholders (30) - Net cash (used in) provided by financing activities (7,502) 2,636 Effect of exchange rate changes on cash (565) 1,245 Net increase (decrease) in cash and cash equivalents 8,343 (2,225) Cash and cash equivalents at the beginning of the period 16,909 25,766					
Repayments of long-term debt (1,754) (40,402) Dividends paid (6,213) (5,413) Stock options exercised, other (925) 146 Proceeds from sale of common stock, net of related expenses - 48,143 Excess tax benefit related to stock option exercises 1,420 162 Distributions to noncontrolling shareholders (30) - Net cash (used in) provided by financing activities (7,502) 2,636 Effect of exchange rate changes on cash (565) 1,245 Net increase (decrease) in cash and cash equivalents 8,343 (2,225) Cash and cash equivalents at the beginning of the period 16,909 25,766	Cash flows from financing activities				
Dividends paid (6,213) (5,413) Stock options exercised, other (925) 146 Proceeds from sale of common stock, net of related expenses - 48,143 Excess tax benefit related to stock option exercises 1,420 162 Distributions to noncontrolling shareholders (30) - Net cash (used in) provided by financing activities (7,502) 2,636 Effect of exchange rate changes on cash (565) 1,245 Net increase (decrease) in cash and cash equivalents 8,343 (2,225) Cash and cash equivalents at the beginning of the period 16,909 25,766			(1.754)		(40.402)
Stock options exercised, other (925) 146 Proceeds from sale of common stock, net of related expenses - 48,143 Excess tax benefit related to stock option exercises 1,420 162 Distributions to noncontrolling shareholders (30) - Net cash (used in) provided by financing activities (7,502) 2,636 Effect of exchange rate changes on cash (565) 1,245 Net increase (decrease) in cash and cash equivalents 8,343 (2,225) Cash and cash equivalents at the beginning of the period 16,909 25,766					
Proceeds from sale of common stock, net of related expenses 48,143 Excess tax benefit related to stock option exercises 1,420 162 Distributions to noncontrolling shareholders (30) - Net cash (used in) provided by financing activities (7,502) 2,636 Effect of exchange rate changes on cash (565) 1,245 Net increase (decrease) in cash and cash equivalents 8,343 (2,225) Cash and cash equivalents at the beginning of the period 16,909 25,766	•		,		,
Excess tax benefit related to stock option exercises 1,420 162 Distributions to noncontrolling shareholders (30) - Net cash (used in) provided by financing activities (7,502) 2,636 Effect of exchange rate changes on cash (565) 1,245 Net increase (decrease) in cash and cash equivalents 8,343 (2,225) Cash and cash equivalents at the beginning of the period 16,909 25,766			(020)		
Distributions to noncontrolling shareholders (30) - Net cash (used in) provided by financing activities (7,502) 2,636 Effect of exchange rate changes on cash (565) 1,245 Net increase (decrease) in cash and cash equivalents 8,343 (2,225) Cash and cash equivalents at the beginning of the period 16,909 25,766	·		1 420		- , -
Net cash (used in) provided by financing activities (7,502) 2,636 Effect of exchange rate changes on cash (565) 1,245 Net increase (decrease) in cash and cash equivalents 8,343 (2,225) Cash and cash equivalents at the beginning of the period 16,909 25,766	•		, -		102
Effect of exchange rate changes on cash (565) 1,245 Net increase (decrease) in cash and cash equivalents 8,343 (2,225) Cash and cash equivalents at the beginning of the period 16,909 25,766	· · · · · · · · · · · · · · · · · · ·	_		_	2 636
Net increase (decrease) in cash and cash equivalents 8,343 (2,225) Cash and cash equivalents at the beginning of the period 16,909 25,766	ivet cash (used in) provided by linancing activities		(7,302)		2,030
Cash and cash equivalents at the beginning of the period 16,909 25,766	Effect of exchange rate changes on cash		(565)		1,245
	Net increase (decrease) in cash and cash equivalents		8,343		(2,225)
Cash and cash equivalents at the end of the period \$\frac{\$\\$25,252}{\$}\$\$ \$\frac{\$\\$23,541}{\$}\$\$	Cash and cash equivalents at the beginning of the period		16,909		25,766
	Cash and cash equivalents at the end of the period	\$	25,252	\$	23,541

SOURCE Quaker Chemical Corporation

Margaret M. Loebl, Vice President, CFO & Treasurer, +1-610-832-4160